- Xtandi patient on Medicare — with supplement — pays $441.97 per month
- 2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology
- WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDS
- Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&D
- China: as PCT patent filings increase, GDP growth has decreased
- Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countries
- KEI comment on USTR's 2016 Special 301 report
- Transparency of patents on medicines and other technologies
- WHO releases program of work and progress report in advance of Consultative Expert Working Group on R&D (2-4 May 2016)
- 2015 Oct 16 version: RCEP draft text for investment chapter
My presentation at IX CODAIP, Curitiba, Brazil, on Copyright norms in treaties & trade agreements - what possibly can go wrong?.
For Immediate Release
3 November 2015
Contact: Zack Struver, +1 (202) 332-2670 or firstname.lastname@example.org
Geneva — The World Trade Organization is poised to announce this Friday its approval of a limited 17-year extension of a 2001 waiver of obligations in the TRIPS Agreement, set to expire at the end of this year, the terms of which exempt Least Developed Countries (LDCs) from requirements to grant patents or related intellectual property rights on pharmaceutical products.
As candidates consider parallel trade in pharmaceutical drugs, a practice blocked by Obama during his presidency, here is how common it is in Europe, where it is regulated and mainstream, as reported in the EFPIA publication, the Pharmaceutical Industry in Figures. Key data, 2015.
On October 23, 2015, the Harvard T.H. Chan School of Public Health hosted a forum titled "Drug Pricing: Public Health Implications," hosted by Caroline Humer, a Reuters healthcare correspondent. The forum featured a panel of four individuals who work on drug pricing:
- Steven Pearson, President of the Institute for Clinical and Economic Review and Lecturer at Harvard Medical School
I was recently asked by OSF to write a two page document that described "what was wrong with the current system of funding R&D?" and to offer some "important ideas for change." This was my two page submission.
What is wrong with the current system for funding R&D? What are the most important ideas for change?
(In two pages, for OSF meeting on drug development)
October 20, 2015
1. What is wrong with the current system for funding R&D?
Rep. Eshoo (D-CA) Sends Letter to USTR Requesting Clarification Regarding Conflicts in TPP Language on Damages and BPCIA, ISDSSubmitted by Andrew Goldman on 20. October 2015 - 17:31
On Tuesday October 20, 2015, Representative Anna Eshoo (D-CA), one of the principal authors of the Biologic Price Competition and Innovation Act (BPCIA), sent a letter to the United States Trade Representative requesting timely clarification regarding the Trans-Pacific Partnership's impact "on existing U.S. laws that limit damages for infringement of intellectual property (IP) rights, and on the potential ISDS ramifications for those conflicts."
Le Mardi 6 Octobre j’ai eu l’opportunité de présenter à la journée “Les connaissances scientifiques : biens privés, publics ou communs?” qui à eu lieu à Paris. Ceci était une occasion pour discuter les “conflits de pouvoir en matière de gouvernance des connaissances scientifiques.”
Six NGOs — including Oxfam America, Health GAP, Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT), the Young Professionals Chronic Disease Network (YP-CDN), and Public Citizen — sent a letter to President Obama today asking him to publicly express the United States’ “full and unconditional support” for the waiver of World Trade Organization (WTO) drug patent rules for Least Developed Countries (LDCs).
Contrast in privilege: US officials working to block WTO LDC drug patent waiver, and people affected by policySubmitted by James Love on 17. October 2015 - 16:57
On the left, the people in the Obama Administration trying to block a permanent waiver of WTO drug patent obligations for Least Developed Countries (as defined by the UN). On the right, some people living in least developed countries.
Ambassador Michael Forman. Head of USTR. Alma maters: Princeton, Oxford and Harvard Law. Formerly ran a hedge fund for Citibank.
On Wednesday, October 14, 2015, KEI staff and members of Public Citizen's Global Access to Medicines team demonstrated outside of the White House and USTR, urging the administration, especially USTR and Ambassador Michael Froman, to support a request for a permanent drug patent waiver for Least Developed Countries (LDCs) at the WTO.
Below are images from the protest action, also available in higher resolution here. And, yes, you can use these photos under any creative commons or wikimedia license.
In the early hours of Thursday morning, 15 October 2015, the WIPO General Assembly adopted the following decision related to the future work of the Standing Committee on Copyright and Related Rights (SCCR). There was no consensus on future work so the Assembly directed the SCCR to "continue its work" on the protection of broadcasting organizations and copyright limitations and exceptions.
Below you will find a collection of articles in the press and commentary by KEI relating to the request for LDC patent exemption on pharmaceutical products at the WTO.
Attached is a letter, dated October 14, 2015, from Senator Sherrod Brown to USTR's Ambassador Michael Froman, urging USTR to support a permanent waiver of WTO drug patent rules, for Least Developed Countries. Negotiations on this issue begin formally on October 15, 2015, during a meeting of the WTO TRIPS Council.
Among the money quotes:
Final draft, India National IPR Policy, by IP Think Tank constituted by DIPP, Ministry of Commerce and IndustrySubmitted by KEI Staff on 14. October 2015 - 5:47
This is a copy of recommendations for an Indian National IPR Policy, written by the "IP Think Tank," which was constituted by the Department of Industrial Policy & Promotion(DIPP), Ministry of Commerce and Industry, Government of India. A copy scanned from a hard copy is here.
The members of the IPR Think Tank were:
- Justice Prabha Sridevan (Retd) - Chairperson
- Mrs. Prathiba M. Singh, Senior Advocate - Member
- Mr. Narendra K. Sabharwal - Member & Convener
The World Intellectual Property Organization's (WIPO) General Assembly is currently engaged five separate informal consultations on the following topics: 1) Lisbon Union, 2) the future of the Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore, 3) the work program of the Standing Committee on Copyright and Related Rights (SCCR), 4) the Design Law Treaty and 5) WIPO External Offices.